274 related articles for article (PubMed ID: 14525995)
1. Thrombin activatable fibrinolysis inhibitor, a potential regulator of vascular inflammation.
Myles T; Nishimura T; Yun TH; Nagashima M; Morser J; Patterson AJ; Pearl RG; Leung LL
J Biol Chem; 2003 Dec; 278(51):51059-67. PubMed ID: 14525995
[TBL] [Abstract][Full Text] [Related]
2. Regulation of tissue inflammation by thrombin-activatable carboxypeptidase B (or TAFI).
Leung LL; Nishimura T; Myles T
Adv Exp Med Biol; 2008; 632():61-9. PubMed ID: 19025114
[TBL] [Abstract][Full Text] [Related]
3. Regulation of tissue inflammation by thrombin-activatable carboxypeptidase B (or TAFI).
Leung LL; Myles T; Nishimura T; Song JJ; Robinson WH
Mol Immunol; 2008 Oct; 45(16):4080-3. PubMed ID: 18706698
[TBL] [Abstract][Full Text] [Related]
4. Monoclonal antibodies targeting the antifibrinolytic activity of activated thrombin-activatable fibrinolysis inhibitor but not the anti-inflammatory activity on osteopontin and C5a.
Semeraro F; Ammollo CT; Gils A; Declerck PJ; Colucci M
J Thromb Haemost; 2013 Dec; 11(12):2137-47. PubMed ID: 24134522
[TBL] [Abstract][Full Text] [Related]
5. Structure-function relationships in thrombin-activatable fibrinolysis inhibitor.
Plug T; Meijers JC
J Thromb Haemost; 2016 Apr; 14(4):633-44. PubMed ID: 26786060
[TBL] [Abstract][Full Text] [Related]
6. What has been learnt from the thrombin-activatable fibrinolysis inhibitor-deficient mouse?
Morser J; Gabazza EC; Myles T; Leung LL
J Thromb Haemost; 2010 May; 8(5):868-76. PubMed ID: 20128866
[TBL] [Abstract][Full Text] [Related]
7. Insights into thrombin activatable fibrinolysis inhibitor function and regulation.
Foley JH; Kim PY; Mutch NJ; Gils A
J Thromb Haemost; 2013 Jun; 11 Suppl 1():306-15. PubMed ID: 23809134
[TBL] [Abstract][Full Text] [Related]
8. Platelet factor 4 inhibits thrombomodulin-dependent activation of thrombin-activatable fibrinolysis inhibitor (TAFI) by thrombin.
Mosnier LO
J Biol Chem; 2011 Jan; 286(1):502-10. PubMed ID: 21041299
[TBL] [Abstract][Full Text] [Related]
9. Thrombin activatable fibrinolysis inhibitor (TAFI) - A possible link between coagulation and complement activation in the antiphospholipid syndrome (APS).
Grosso G; Vikerfors A; Woodhams B; Adam M; Bremme K; Holmström M; Ågren A; Eelde A; Bruzelius M; Svenungsson E; Antovic A
Thromb Res; 2017 Oct; 158():168-173. PubMed ID: 28669410
[TBL] [Abstract][Full Text] [Related]
10. Selective modulation of thrombin-activatable fibrinolysis inhibitor (TAFI) activation by thrombin or the thrombin-thrombomodulin complex using TAFI-derived peptides.
Plug T; Marquart JA; Marx PF; Meijers JC
J Thromb Haemost; 2015 Nov; 13(11):2093-101. PubMed ID: 26341360
[TBL] [Abstract][Full Text] [Related]
11. Elucidation of the molecular mechanisms of two nanobodies that inhibit thrombin-activatable fibrinolysis inhibitor activation and activated thrombin-activatable fibrinolysis inhibitor activity.
Zhou X; Weeks SD; Ameloot P; Callewaert N; Strelkov SV; Declerck PJ
J Thromb Haemost; 2016 Aug; 14(8):1629-38. PubMed ID: 27279497
[TBL] [Abstract][Full Text] [Related]
12. Activated thrombin-activatable fibrinolysis inhibitor attenuates the angiogenic potential of endothelial cells: potential relevance to the breast tumour microenvironment.
Bazzi ZA; Balun J; Cavallo-Medved D; Porter LA; Boffa MB
Clin Exp Metastasis; 2017 Feb; 34(2):155-169. PubMed ID: 28124276
[TBL] [Abstract][Full Text] [Related]
13. Plasma and recombinant thrombin-activable fibrinolysis inhibitor (TAFI) and activated TAFI compared with respect to glycosylation, thrombin/thrombomodulin-dependent activation, thermal stability, and enzymatic properties.
Boffa MB; Wang W; Bajzar L; Nesheim ME
J Biol Chem; 1998 Jan; 273(4):2127-35. PubMed ID: 9442053
[TBL] [Abstract][Full Text] [Related]
14. Activated TAFI Promotes the Development of Chronic Thromboembolic Pulmonary Hypertension: A Possible Novel Therapeutic Target.
Satoh T; Satoh K; Yaoita N; Kikuchi N; Omura J; Kurosawa R; Numano K; Al-Mamun E; Siddique MA; Sunamura S; Nogi M; Suzuki K; Miyata S; Morser J; Shimokawa H
Circ Res; 2017 Apr; 120(8):1246-1262. PubMed ID: 28289017
[TBL] [Abstract][Full Text] [Related]
15. Thrombin activatable fibrinolysis inhibitor: not just an inhibitor of fibrinolysis.
Bajzar L; Jain N; Wang P; Walker JB
Crit Care Med; 2004 May; 32(5 Suppl):S320-4. PubMed ID: 15118538
[TBL] [Abstract][Full Text] [Related]
16. Inactivation of active thrombin-activable fibrinolysis inhibitor takes place by a process that involves conformational instability rather than proteolytic cleavage.
Marx PF; Hackeng TM; Dawson PE; Griffin JH; Meijers JC; Bouma BN
J Biol Chem; 2000 Apr; 275(17):12410-5. PubMed ID: 10777524
[TBL] [Abstract][Full Text] [Related]
17. Thrombin-activable fibrinolysis inhibitor zymogen does not play a significant role in the attenuation of fibrinolysis.
Foley JH; Kim P; Nesheim ME
J Biol Chem; 2008 Apr; 283(14):8863-7. PubMed ID: 18252711
[TBL] [Abstract][Full Text] [Related]
18. Role of zinc ions in activation and inactivation of thrombin-activatable fibrinolysis inhibitor.
Marx PF; Bouma BN; Meijers JC
Biochemistry; 2002 Jan; 41(4):1211-6. PubMed ID: 11802720
[TBL] [Abstract][Full Text] [Related]
19. Generation and characterization of a highly stable form of activated thrombin-activable fibrinolysis inhibitor.
Marx PF; Havik SR; Marquart JA; Bouma BN; Meijers JC
J Biol Chem; 2004 Feb; 279(8):6620-8. PubMed ID: 14660622
[TBL] [Abstract][Full Text] [Related]
20. VhH anti-thrombomodulin clone 1 inhibits TAFI activation and enhances fibrinolysis in human whole blood under flow.
van Moorsel MVA; Poolen GC; Koekman CA; Verhoef S; de Maat S; Barendrecht A; van Kleef ND; Meijers JCM; Schiffelers RM; Maas C; Urbanus RT
J Thromb Haemost; 2022 May; 20(5):1213-1222. PubMed ID: 35170225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
